Cellceutix Corp (CTIX) 1.6900 $CTIX
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
Marketwire - Mon Jun 02, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, reports today that patient enrollment has been completed in the Company's Phase 1 crossover study of its anti-psoriasis drug candidate Prurisol. Cellceutix expects lab results, pharmacokinetic studies, and analysis to take approximately two months. If the data shows bioequivalence of Prurisol with Abacavir Sulfate, the Company will then schedule a meeting with the U.S. Food and Drug Administration regarding initiating a Phase 2/3 trial of Prurisol through the 505(b)(2) regulatory pathway.
Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities
Marketwire - Tue May 27, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the Company has signed material transfer agreements for compounds in its defensin mimetics portfolio with major university laboratories located in New York and New Jersey. These laboratories do significant government work and have expertise in anti-infective, anti-fungal and bio-defense applications. Cellceutix will be shipping the compounds to the university laboratories in the coming weeks. It is hoped that these collaborations will result in government assistance in developing the Company's novel compounds for a broad spectrum of indications.
Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market
Marketwire - Mon May 19, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that its lead antibiotic, Brilacidin(TM), demonstrated visually convincing wound healing properties in a recently completed experiment in a diabetic rat model.
Bio-Matrix Scientific Group, Inc. Sees 37% Increase In Share Price
ACCESSWIRE - Tue May 13, 9:52AM CDT
Bio-Matrix Scientific Group, Inc. (OTCPINK: BMSN) saw its share volume skyrocket on May 12th with 127,306,136 shares exchanging hands, 2.7 times higher than its three month daily average of 46,941,604 shares.
Cellceutix Confident in Its Formidable Antibiotic Arsenal
Marketwire - Mon May 12, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report this update on its clinical trial of Brilacidin(TM) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Psoriasis - Pipeline Review, H1 2014: 110 Companies Profiled
M2 - Thu May 08, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vjq8/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 4SC AG - Acceleron Pharma, Inc. - Addex Therapeutics - Advancell - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Alcon, Inc. - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - AngioLab, Inc. - Apexigen, Inc. - ApoPharma Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Aurinia Pharmaceuticals Inc. - Avexxin AS - Basilea Pharmaceutica AG - Bionomics Limited - Brickell Biotech, Inc. - Can-Fite BioPharma Ltd. - Catabasis Pharmaceuticals, Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Cellceutix Corporation - Celltrion, Inc. For more information visit http://www.researchandmarkets.com/research/p6vjq8/psoriasis
Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - Thu May 08, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis
Marketwire - Wed May 07, 4:55AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the first cohort of patients has successfully completed enrollment in the Company's clinical trial of anti-psoriasis drug candidate Prurisol(TM).
Global Oral Mucositis Clinical Trials Review 2014
M2 - Fri May 02, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxt58q/oral_mucositis) has announced the addition of the "Global Oral Mucositis Clinical Trials Review 2014" report to their offering. Oral Mucositis Global Clinical Trials Review, H1, 2014" provides data on the Oral Mucositis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Mucositis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Mucositis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Amgen Inc. - Swedish Orphan Biovitrum AB - Soligenix, Inc. - Cellceutix Corporation - Jazz Pharmaceuticals plc - Endo International plc - Daewoong Co., Ltd. - CD Pharma India Private Ltd. - Biotec Pharmacon ASA - ActogeniX NV - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Hadassah Medical Organization - University Hospital Freiburg - Radiation Therapy Oncology Group - North Central Cancer Treatment Group - All India Institute of Medical Sciences - The University of Texas Health Science Center at San Antonio - Shahid Beheshti University - UCLA's Jonsson Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/vx..._mucositis
FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment
ACCESSWIRE - Tue Apr 29, 9:05AM CDT
BrainStorm Cell Therapeutics' (OTCQB: BCLI) stock volume skyrocketed Apr. 28, with 3,714,379 shares changing hands, more than 5 times its three-month average volume of 718,105 shares.
Top Five Daily Small Cap Trading List: InVivo Therapeutics Holding Corp, Vapor Group, Inc., Cellceutix Corp, Agenus, Magellan Petroleum Corp
PR Newswire Europe - Tue Apr 29, 9:04AM CDT
LONDON, April 29, 2014 /PRNewswire/ --
Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic
ACCESSWIRE - Mon Apr 28, 8:07AM CDT
Cellceutix Corp. (OTCQB: CTIX) enjoyed strong stock volume Apr. 25, with 180,001 shares changing hands.
Global Oral Mucositis Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9vr8h/oral_mucositis) has announced the addition of the "Global Oral Mucositis Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Oral Mucositis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Oral Mucositis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Daewoong Pharmaceutical Co., Ltd. - Soligenix, Inc. - BioAlliance Pharma SA - Sucampo Pharmaceuticals, Inc. - ActogeniX NV - Alder Biopharmaceuticals Inc. - Promedior, Inc. - ProCertus BioPharm Inc. - GliaMed, Inc. - Avaxia Biologics, Inc. - Cellceutix Corporation - Vicus Therapeutics, LLC - Nephrx Corporation - Laila Pharmaceuticals Pvt. Ltd. - Applied Protein Sciences, LLC Drug Profiles - nepidermin - Lactobacillus CD2 Lozenges - sucralfate - clonidine hydrochloride ER - clazakizumab - SGX-942 - LP-004-09 - methionine - Quercetin - selenium sulfide - AG-013 - cobiprostone - GC-4403 - GM-1485 - brilacidin - PRM-151 - NX-002 - Hybrid Adenoretroviral Vectors - Regenasyn - GC-4419 - AP-002 - AP-001 - OralX - (captopril teprenone) - Anti-TNF Antibody For Oral Mucositis For more information visit http://www.researchandmarkets.com/research/l9..._mucositis
Global Candidiasis Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr2b6p/candidiasis) has announced the addition of the "Global Candidiasis Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - Sequella, Inc. - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - Novartis AG - Eisai Co., Ltd. - iCo Therapeutics Inc. - Almirall, S.A. - Basilea Pharmaceutica AG - Pacgen Life Science Corporation - NovaDigm Therapeutics, Inc. - Cellceutix Corporation - Aureogen Biosciences, Inc. - Sealife PHARMA GMBH - Panacela Labs, Inc. - Biomar Microbial Technologies Drug Profiles - posaconazole - isavuconazonium - PAC-113 - LAS-41003 - NDV-3 Vaccine - SQ-109 - PMX-30016 - amphotericin B - E-1210 - SLP-0901 - D11-2040 - Xenomycin - AUGC-15 - Compound-18545 - Compound-9403 - PMX-1502 - PMX-519 - Candida Vaccine - PMX-1408 - E-1211 - SLP-1002 - SLP-0907 - Drugs for Fungal Infections - Small Molecules for Candidiasis - Compound-14844 - Program For Women Health - PMX-70004 - PMX-1570 - PMX-1576 - PMX-1591 - PMX-1625 - Small Molecules for Aspergillosis and Candidiasis - Small Molecules for Candidiasis - Drugs for Fungal Infections - PAC-113 For more information visit http://www.researchandmarkets.com/research/xr...andidiasis
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae
Marketwire - Mon Apr 14, 5:30AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report favorable results in a recently completed preclinical study evaluating its novel antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae. The research, which is government funded through existing grants to research institutions, is being conducted at a major university in Texas.
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
Marketwire - Mon Jun 02, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, reports today that patient enrollment has been completed in the Company's Phase 1 crossover study of its anti-psoriasis drug candidate Prurisol. Cellceutix expects lab results, pharmacokinetic studies, and analysis to take approximately two months. If the data shows bioequivalence of Prurisol with Abacavir Sulfate, the Company will then schedule a meeting with the U.S. Food and Drug Administration regarding initiating a Phase 2/3 trial of Prurisol through the 505(b)(2) regulatory pathway. Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities
Marketwire - Tue May 27, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the Company has signed material transfer agreements for compounds in its defensin mimetics portfolio with major university laboratories located in New York and New Jersey. These laboratories do significant government work and have expertise in anti-infective, anti-fungal and bio-defense applications. Cellceutix will be shipping the compounds to the university laboratories in the coming weeks. It is hoped that these collaborations will result in government assistance in developing the Company's novel compounds for a broad spectrum of indications. Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market
Marketwire - Mon May 19, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that its lead antibiotic, Brilacidin(TM), demonstrated visually convincing wound healing properties in a recently completed experiment in a diabetic rat model. Bio-Matrix Scientific Group, Inc. Sees 37% Increase In Share Price
ACCESSWIRE - Tue May 13, 9:52AM CDT
Bio-Matrix Scientific Group, Inc. (OTCPINK: BMSN) saw its share volume skyrocket on May 12th with 127,306,136 shares exchanging hands, 2.7 times higher than its three month daily average of 46,941,604 shares.
Cellceutix Confident in Its Formidable Antibiotic Arsenal
Marketwire - Mon May 12, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report this update on its clinical trial of Brilacidin(TM) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Psoriasis - Pipeline Review, H1 2014: 110 Companies Profiled
M2 - Thu May 08, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vjq8/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 4SC AG - Acceleron Pharma, Inc. - Addex Therapeutics - Advancell - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Alcon, Inc. - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - AngioLab, Inc. - Apexigen, Inc. - ApoPharma Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Aurinia Pharmaceuticals Inc. - Avexxin AS - Basilea Pharmaceutica AG - Bionomics Limited - Brickell Biotech, Inc. - Can-Fite BioPharma Ltd. - Catabasis Pharmaceuticals, Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Cellceutix Corporation - Celltrion, Inc. For more information visit http://www.researchandmarkets.com/research/p6vjq8/psoriasis
Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - Thu May 08, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis
Marketwire - Wed May 07, 4:55AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the first cohort of patients has successfully completed enrollment in the Company's clinical trial of anti-psoriasis drug candidate Prurisol(TM). Global Oral Mucositis Clinical Trials Review 2014
M2 - Fri May 02, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxt58q/oral_mucositis) has announced the addition of the "Global Oral Mucositis Clinical Trials Review 2014" report to their offering. Oral Mucositis Global Clinical Trials Review, H1, 2014" provides data on the Oral Mucositis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Mucositis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Mucositis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Amgen Inc. - Swedish Orphan Biovitrum AB - Soligenix, Inc. - Cellceutix Corporation - Jazz Pharmaceuticals plc - Endo International plc - Daewoong Co., Ltd. - CD Pharma India Private Ltd. - Biotec Pharmacon ASA - ActogeniX NV - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Hadassah Medical Organization - University Hospital Freiburg - Radiation Therapy Oncology Group - North Central Cancer Treatment Group - All India Institute of Medical Sciences - The University of Texas Health Science Center at San Antonio - Shahid Beheshti University - UCLA's Jonsson Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/vx..._mucositis
FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment
ACCESSWIRE - Tue Apr 29, 9:05AM CDT
BrainStorm Cell Therapeutics' (OTCQB: BCLI) stock volume skyrocketed Apr. 28, with 3,714,379 shares changing hands, more than 5 times its three-month average volume of 718,105 shares.
Top Five Daily Small Cap Trading List: InVivo Therapeutics Holding Corp, Vapor Group, Inc., Cellceutix Corp, Agenus, Magellan Petroleum Corp
PR Newswire Europe - Tue Apr 29, 9:04AM CDT
LONDON, April 29, 2014 /PRNewswire/ --
Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic
ACCESSWIRE - Mon Apr 28, 8:07AM CDT
Cellceutix Corp. (OTCQB: CTIX) enjoyed strong stock volume Apr. 25, with 180,001 shares changing hands.
Global Oral Mucositis Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9vr8h/oral_mucositis) has announced the addition of the "Global Oral Mucositis Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Oral Mucositis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Oral Mucositis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Daewoong Pharmaceutical Co., Ltd. - Soligenix, Inc. - BioAlliance Pharma SA - Sucampo Pharmaceuticals, Inc. - ActogeniX NV - Alder Biopharmaceuticals Inc. - Promedior, Inc. - ProCertus BioPharm Inc. - GliaMed, Inc. - Avaxia Biologics, Inc. - Cellceutix Corporation - Vicus Therapeutics, LLC - Nephrx Corporation - Laila Pharmaceuticals Pvt. Ltd. - Applied Protein Sciences, LLC Drug Profiles - nepidermin - Lactobacillus CD2 Lozenges - sucralfate - clonidine hydrochloride ER - clazakizumab - SGX-942 - LP-004-09 - methionine - Quercetin - selenium sulfide - AG-013 - cobiprostone - GC-4403 - GM-1485 - brilacidin - PRM-151 - NX-002 - Hybrid Adenoretroviral Vectors - Regenasyn - GC-4419 - AP-002 - AP-001 - OralX - (captopril teprenone) - Anti-TNF Antibody For Oral Mucositis For more information visit http://www.researchandmarkets.com/research/l9..._mucositis
Global Candidiasis Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr2b6p/candidiasis) has announced the addition of the "Global Candidiasis Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - Sequella, Inc. - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - Novartis AG - Eisai Co., Ltd. - iCo Therapeutics Inc. - Almirall, S.A. - Basilea Pharmaceutica AG - Pacgen Life Science Corporation - NovaDigm Therapeutics, Inc. - Cellceutix Corporation - Aureogen Biosciences, Inc. - Sealife PHARMA GMBH - Panacela Labs, Inc. - Biomar Microbial Technologies Drug Profiles - posaconazole - isavuconazonium - PAC-113 - LAS-41003 - NDV-3 Vaccine - SQ-109 - PMX-30016 - amphotericin B - E-1210 - SLP-0901 - D11-2040 - Xenomycin - AUGC-15 - Compound-18545 - Compound-9403 - PMX-1502 - PMX-519 - Candida Vaccine - PMX-1408 - E-1211 - SLP-1002 - SLP-0907 - Drugs for Fungal Infections - Small Molecules for Candidiasis - Compound-14844 - Program For Women Health - PMX-70004 - PMX-1570 - PMX-1576 - PMX-1591 - PMX-1625 - Small Molecules for Aspergillosis and Candidiasis - Small Molecules for Candidiasis - Drugs for Fungal Infections - PAC-113 For more information visit http://www.researchandmarkets.com/research/xr...andidiasis
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae
Marketwire - Mon Apr 14, 5:30AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report favorable results in a recently completed preclinical study evaluating its novel antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae. The research, which is government funded through existing grants to research institutions, is being conducted at a major university in Texas. 
